GlassScriptPhysician profile
Hamid R Bahadori
NPI 1861571887
$28,724.29
in general payments reported to CMS, 2019-2025
82 companies · $4,697 in 2025
The $4,697 reported for 2025 was more than what 84% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,088 · 2020: $3,230 · 2021: $4,291 · 2022: $4,658 · 2023: $4,270 · 2024: $4,489 · 2025: $4,697.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $20.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,436.36 |
| Education | $20.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,235.66 | 2019-2025 | |
| Ucb, INC. | $2,080.07 | 2019-2025 | Nayzilam, Briviact, Rystiggo |
| Abbvie INC. | $1,722.47 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Sk Life Science, INC. | $1,641.93 | 2020-2025 | |
| Acadia Pharmaceuticals INC | $1,320.47 | 2019-2025 | Nuplazid |
| Pfizer INC. | $1,275.08 | 2021-2025 | |
| Emd Serono, INC. | $1,273.95 | 2019-2025 | Mavenclad |
| Teva Pharmaceuticals USA, INC. | $1,219.15 | 2019-2025 | Ajovy, Austedo Xr, Austedo |
| Lundbeck LLC | $934.20 | 2020-2025 | Vyepti, Rexulti |
| Biogen, INC. | $789.25 | 2019-2025 | Leqembi, Skyclarys, Tysabri |
| Lilly USA, LLC | $732.37 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Genzyme Corporation | $716.66 | 2019-2025 | |
| Genentech USA, INC. | $688.94 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Amgen INC. | $688.53 | 2019-2025 | Uplizna, Aimovig |
| Amneal Pharmaceuticals LLC | $652.76 | 2019-2025 | Crexont, Rytary, Ongentys 50mg Capsules 30 |
Show all 82 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hamid Bahadori listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.